A multi-centre open label continuation study with subcutaneous D2E7 (adalimumab) for patients with rheumatoid arthritis who completed a preceding clinical study with D2E7 (adalimumab)

Trial Profile

A multi-centre open label continuation study with subcutaneous D2E7 (adalimumab) for patients with rheumatoid arthritis who completed a preceding clinical study with D2E7 (adalimumab)

Completed
Phase of Trial: Phase III

Latest Information Update: 21 Nov 2011

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Most Recent Events

    • 21 Nov 2011 Actual patient number is 796 according to ClinicalTrials.gov.
    • 21 Nov 2011 Actual end date (June 2006) added as reported by ClinicalTrials.gov.
    • 28 Aug 2007 Status change from in progress to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top